Core Viewpoint - The article discusses the initiation of the TRIUMPH-7 Phase III clinical trial by Eli Lilly, which aims to evaluate the efficacy and safety of Retatrutide in patients with obesity or overweight and chronic low back pain, marking the first global Phase III study of GLP1R/GIPR/GCGR triple agonists for pain treatment [2][3]. Group 1 - TRIUMPH-7 is a randomized, double-blind, placebo-controlled international multicenter study expected to start in June 2025 and complete by September 2027 [3]. - The trial plans to enroll 586 participants who will be randomly assigned to receive either weekly injections of Retatrutide or a placebo for 80 weeks [3]. - Primary endpoints include the change in pain intensity from baseline and the percentage change in weight from baseline, while secondary endpoints cover the number of patients achieving pain relief and weight loss targets [3]. Group 2 - Retatrutide is classified as a GLP1R/GIPR/GCGR triple agonist and is currently the fastest advancing candidate in this field, undergoing Phase III trials for multiple indications including obesity, type 2 diabetes, secondary prevention of cardiovascular events, and obstructive sleep apnea [3].

弘则研究-减肥药下一个爆款在哪里 20250624 摘要 全球减肥药市场潜力巨大，预计未来将达到 1,500 亿美元规模，其中口 服制剂或占据主导地位，达到 800 亿美元。礼来和诺和诺德是市场主要 参与者，但新靶点和给药方式的创新将重塑市场格局。 司美格鲁肽在中国市场销售额显著，但专门减肥版本销售未达预期，可 能因糖尿病版本替代。替尔泊泰已上市，但市场策略相对保守。未来价 格竞争和市场渗透率将是关键。 减肥药的消费属性突出，临床数据并非唯一决定因素。仿制药冲击较小， 用药周期短，停药后体重反弹是挑战。新研发方向包括减少肌肉损失、 降低不良反应、开发口服和超长效制剂。 减肥速度并非越快越好，需平衡安全性。在 GLP-1 和 GIPR 靶点基础上， 剂量和制剂调整可能影响效果和副作用。新靶点如 CCC 和 AMPK 具有 潜力，可减少肌肉下降和调节代谢水平。 安全性是减肥药的关键，尤其对健康人群。肌肉损失的可接受程度需综 合考虑消费品属性和口碑影响。小核酸药物在增肌类产品中展现前景， 其安全性优势可能改变市场格局。 Q&A 当前核心减肥机制基于 GLP-1 和 GIPR 靶点，通过控制中枢神经系统降低食欲， 并 ...

Core Insights - Hanyu Pharmaceutical has entered the dosage maintenance phase for its Semaglutide injection project, with plans to apply for market approval in China by 2026 [1] Company Developments - The company is developing HY3003, a GLP-1R/GIPR/GCGR receptor agonist for weight loss, utilizing AI peptide chip technology for candidate selection [1] - Hanyu has completed preclinical candidate screening and raw material process development, now moving into the raw material pilot scale-up phase [1] - In addition to the weight loss drug, the company is also working on an innovative drug, HY3000 nasal spray, aimed at preventing coronavirus infections, which is currently in Phase III clinical trials [1] Collaborations and Innovations - Hanyu is collaborating with China National Pharmaceutical Group on the research and commercialization of Cannabidiol (CBD) innovative drugs, integrating peptide and small nucleic acid drug technologies [1] - The company has completed enrollment of all participants in the Phase III clinical trial for Semaglutide injection as of January this year and is currently in the follow-up phase [1]

目前，HS-20094 正在中国进行 III 期临床试验，国内肥胖症的 3 期试验和糖尿病的 2b 期研究也在同步推进。若后续试验顺利完成，HS-20094 有望为全球众 多糖尿病及肥胖症患者带来全新的治疗选择。 根据协议，翰森制药将获得8000万美元首付款，并有资格根据该产品开发、注册审批和商业化进展收取最高19.3亿美元里程碑付款，以及未来潜在产品销售 的双位数百分比特许权使用费。（总包超20亿美元：8000万美元首付款＋19.3亿美元里程碑＋潜在销售双位数百分比）。 HS-20094：潜力巨大的在研药物 HS-20094是一款在研GLP-1/GIP双受体激动剂，已在多项 II 期临床试验中崭露头角，展现出积极的疗效和安全性数据。 它通过选择性激活 GLP-1 受体和 GIP 受体，能够促进胰岛素分泌，延缓胃排空，并抑制食欲减少进食量，进而产生控糖、减重及代谢改善等一系列生物学 效应。其给药方式为每周一次皮下注射，极大地方便了患者使用。 | HS-20094 | | | | --- | --- | --- | | | HS-20094 | | | 药品名称 | 研发代码:HS-20094 | | | | ...

医药 本周医药板块上涨 1.27%，百济 BTK PROTAC 启动头对头 3 期临 床 证券研究报告 | 行业周报 2025 年 05 月 19 日 | 股票 | 股票 | 投资 | EPS （元） | | PE | | | --- | --- | --- | --- | --- | --- | --- | | 代码 | 名称 | 评级 | 2025E | 2026E | 2025E | 2026E | | 002755.SZ | 奥赛康 | 买入 | 0.2 | 0.28 | 87.7 | 62.64 | | 01952.HK | 云顶新耀 | 买入 | -0.94 | 0.58 | - | - | | 600079.SH | 人福医药 | 增持 | 1.59 | 1.86 | 12.83 | 10.97 | | 688192.SH | 迪哲医药 | 增持 | -1.33 | -0.08 | - | - | | 688315.SH | 诺禾致源 | 买入 | 0.53 | 0.62 | 26.51 | 22.66 | | 688321.SH | 微芯生物 | 增持 | 0.05 | 0.23 | 349. ...